Loading clinical trials...
Loading clinical trials...
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06840003 IN PATIENTS WITH MALIGNANT GLIOMAS
This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
UCLA Clinical & Translational Research Center
Los Angeles, California, United States
UCLA Oncology Center
Los Angeles, California, United States
UCLA School of Medicine
Los Angeles, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham & Women's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
Columbia University Medical Center
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Start Date
September 9, 2016
Primary Completion Date
December 26, 2018
Completion Date
December 26, 2018
Last Updated
January 27, 2020
17
ACTUAL participants
PF-06840003
DRUG
Lead Sponsor
Pfizer
NCT05099003
NCT06860594
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05839379